These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 38388379)

  • 1. From pixels to patient care: deep learning-enabled pathomics signature offers precise outcome predictions for immunotherapy in esophageal squamous cell cancer.
    Li B; Qin W; Yang L; Li H; Jiang C; Yao Y; Cheng S; Zou B; Fan B; Dong T; Wang L
    J Transl Med; 2024 Feb; 22(1):195. PubMed ID: 38388379
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Programmed cell death-ligand 1 expression predicts poor treatment response and prognostic value in esophageal squamous cell carcinoma patients without esophagectomy.
    Zhang F; Zhu X; Zhang Q; Zhou P; Hao L
    Aging (Albany NY); 2021 Jul; 13(14):18827-18838. PubMed ID: 34297698
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcome-Supervised Deep Learning on Pathologic Whole Slide Images for Survival Prediction of Immunotherapy in Patients with Non-Small Cell Lung Cancer.
    Li B; Yang L; Zhang H; Li H; Jiang C; Yao Y; Cheng S; Zou B; Fan B; Dong T; Wang L
    Mod Pathol; 2023 Aug; 36(8):100208. PubMed ID: 37149222
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessing PD-L1 expression in non-small cell lung cancer and predicting responses to immune checkpoint inhibitors using deep learning on computed tomography images.
    Tian P; He B; Mu W; Liu K; Liu L; Zeng H; Liu Y; Jiang L; Zhou P; Huang Z; Dong D; Li W
    Theranostics; 2021; 11(5):2098-2107. PubMed ID: 33500713
    [No Abstract]   [Full Text] [Related]  

  • 5. Comprehensive Analysis of PD-L1 Expression, Immune Infiltrates, and m6A RNA Methylation Regulators in Esophageal Squamous Cell Carcinoma.
    Guo W; Tan F; Huai Q; Wang Z; Shao F; Zhang G; Yang Z; Li R; Xue Q; Gao S; He J
    Front Immunol; 2021; 12():669750. PubMed ID: 34054840
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical benefits of PD-1 inhibitors in specific subgroups of patients with advanced esophageal squamous cell carcinoma: a systematic review and meta-analysis of phase 3 randomized clinical trials.
    Lu Y; Wang W; Wang F
    Front Immunol; 2023; 14():1171671. PubMed ID: 37205107
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development and interpretation of a pathomics-driven ensemble model for predicting the response to immunotherapy in gastric cancer.
    Han Z; Zhang Z; Yang X; Li Z; Sang S; Islam MT; Guo AA; Li Z; Wang X; Wang J; Zhang T; Sun Z; Yu L; Wang W; Xiong W; Li G; Jiang Y
    J Immunother Cancer; 2024 May; 12(5):. PubMed ID: 38749538
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Programmed death ligand-1 expression and its prognostic role in esophageal squamous cell carcinoma.
    Kim R; Keam B; Kwon D; Ock CY; Kim M; Kim TM; Kim HJ; Jeon YK; Park IK; Kang CH; Kim DW; Kim YT; Heo DS
    World J Gastroenterol; 2016 Oct; 22(37):8389-8397. PubMed ID: 27729745
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advancements in immunotherapy for advanced esophageal squamous cell carcinoma: a comprehensive review of current strategies and future directions.
    Zhang Y; Li Z; Huang Y; Xu Y; Zou B
    Expert Rev Clin Immunol; 2024 Aug; 20(8):971-984. PubMed ID: 38884604
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PD-L1 expression and its clinicopathological correlation in advanced esophageal squamous cell carcinoma in a Chinese population.
    Rong L; Liu Y; Hui Z; Zhao Z; Zhang Y; Wang B; Yuan Y; Li W; Guo L; Ying J; Song Y; Wang L; Zhou Z; Xue L; Lu N
    Diagn Pathol; 2019 Jan; 14(1):6. PubMed ID: 30684971
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A fibroblast-associated signature predicts prognosis and immunotherapy in esophageal squamous cell cancer.
    Ren Q; Zhang P; Zhang X; Feng Y; Li L; Lin H; Yu Y
    Front Immunol; 2023; 14():1199040. PubMed ID: 37313409
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic significance of tumor-infiltrating immune cells and PD-L1 expression in esophageal squamous cell carcinoma.
    Jiang Y; Lo AWI; Wong A; Chen W; Wang Y; Lin L; Xu J
    Oncotarget; 2017 May; 8(18):30175-30189. PubMed ID: 28404915
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhancer demethylation-regulated gene score identified molecular subtypes, inspiring immunotherapy or CDK4/6 inhibitor therapy in oesophageal squamous cell carcinoma.
    Gao W; Liu S; Wu Y; Wei W; Yang Q; Li W; Chen H; Luo A; Wang Y; Liu Z
    EBioMedicine; 2024 Jul; 105():105177. PubMed ID: 38924839
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RATIONALE 311: tislelizumab plus concurrent chemoradiotherapy for localized esophageal squamous cell carcinoma.
    Yu R; Wang W; Li T; Li J; Zhao K; Wang W; Liang L; Wu H; Ai T; Huang W; Li L; Yu W; Wei C; Wang Y; Shen W; Xiao Z
    Future Oncol; 2021 Nov; 17(31):4081-4089. PubMed ID: 34269067
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Construction of a prognostic model for extensive-stage small cell lung cancer patients undergoing immune therapy in northernmost China and prediction of treatment efficacy based on response status at different time points.
    Dang J; Xu G; Guo G; Zhang H; Shang L
    J Cancer Res Clin Oncol; 2024 May; 150(5):255. PubMed ID: 38750370
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic significance of epidermal growth factor receptor and programmed cell death-ligand 1 co-expression in esophageal squamous cell carcinoma.
    Jiang G; Miao Y; Wang Z; Zhang Q; Zhou P; Zhang F
    Aging (Albany NY); 2023 Feb; 15(4):1107-1129. PubMed ID: 36812484
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification and validation of an autophagy-related gene signature for predicting prognosis in patients with esophageal squamous cell carcinoma.
    Shi X; Li Y; Pan S; Liu X; Ke Y; Guo W; Wang Y; Ruan Q; Zhang X; Ma H
    Sci Rep; 2022 Feb; 12(1):1960. PubMed ID: 35121801
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Programmed death-ligand 1 is prognostic factor in esophageal squamous cell carcinoma and is associated with epidermal growth factor receptor.
    Zhang W; Pang Q; Zhang X; Yan C; Wang Q; Yang J; Yu S; Liu X; Pan Y; Yuan Z; Wang P; Xiao Z
    Cancer Sci; 2017 Apr; 108(4):590-597. PubMed ID: 28192623
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of Sialic Acid-Binding Immunoglobulin-Like Lectin 15 With Phenotypes in Esophageal Squamous Cell Carcinoma in the Setting of Neoadjuvant Chemoradiotherapy.
    Zhou S; Wang Y; Zhang R; Zeng W; Liu S; Liu S; Liu M; Yang H; Xi M
    JAMA Netw Open; 2023 Jan; 6(1):e2250965. PubMed ID: 36648946
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predicting benefit from immune checkpoint inhibitors in patients with non-small-cell lung cancer by CT-based ensemble deep learning: a retrospective study.
    Saad MB; Hong L; Aminu M; Vokes NI; Chen P; Salehjahromi M; Qin K; Sujit SJ; Lu X; Young E; Al-Tashi Q; Qureshi R; Wu CC; Carter BW; Lin SH; Lee PP; Gandhi S; Chang JY; Li R; Gensheimer MF; Wakelee HA; Neal JW; Lee HS; Cheng C; Velcheti V; Lou Y; Petranovic M; Rinsurongkawong W; Le X; Rinsurongkawong V; Spelman A; Elamin YY; Negrao MV; Skoulidis F; Gay CM; Cascone T; Antonoff MB; Sepesi B; Lewis J; Wistuba II; Hazle JD; Chung C; Jaffray D; Gibbons DL; Vaporciyan A; Lee JJ; Heymach JV; Zhang J; Wu J
    Lancet Digit Health; 2023 Jul; 5(7):e404-e420. PubMed ID: 37268451
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.